top of page
Petri Dishes


Sano has acquired technology from Texas A&M University for a novel first-in-class therapeutic for the treatment of serious Gram-positive infections. Mutacin 1140 analogs hold significant promise for the treatment of Gram-positive pathogens, and several have been identified for clinical development. A careful understanding of the structural elements that do not interfere with the antibiotic’s bioactivity or interfere with the antibiotic’s post-translational modifications was necessary. Therapeutic leads with potent activity against MRSA and S. pneumoniae that have improved pharmacokinetic properties and a demonstrated efficacy are being developed into a novel MRSA therapeutic and a novel treatment for a systemic bacterial infection.

Image by Photoholgic

What is Mutacin?

Mutacin is a first-in-class therapeutic for the treatment of Gram-positive infections. Due to its unique mechanism of action it is active against vancomycin and methicillin resistant Gram-positive pathogens.

How is it made?

Mutacin is isolated from our proprietary bacterial strains at our own facilities. We utilize industry-standard equipment and techniques to cultivate and harvest the bacteria before isolating the valuable mutacin from the culture.

Image by Elevate
Image by National Cancer Institute

Preclinical Superiority

Mutacin has been demonstrated superiority to vancomycin in a preclinical methicillin-resistant Staphylococcus aureus systemic infection model.

Fighting Antimicrobial Resistance

Drug-resistant bacterial infections are becoming an increasing threat with the decline of investment into novel antimicrobials. Mutacin is part of a resurgence in the development of the antimicrobial pipeline that will stave off the dangers of drug-resistant pathogens.

Image by CDC
bottom of page